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Genes Associated With Prognosis After Surgery
For Malignant Pleural Mesothelioma Promote
Tumor Cell Survival In Vitro
Gavin J Gordon, Raphael Bueno and David J Sugarbaker
*
Abstract
Background: Mesothelioma is an aggressive neoplasm with few effective treatments, one being cytoreductive
surgery. We previously described a test, based on differential expression levels of four genes, to predict clinical
outcome in prospectively consented mesothelioma patients after surgery. In this study, we determined whether
any of these four genes could be linked to a cancer relevant phenotype.
Methods: We conducted a high-throughput RNA inhibition screen to knockdown gene expression levels of the
four genes comprising the test (ARHGDIA, COBLL1, PKM2, TM4SF1) in both a human lung-derived normal and a
tumor cell line using three different small inhibitory RNA molecules per gene. Successful knockdown was
confirmed using quantitative RT-PCR. Detection of statistically significant changes in apoptosis and mitosis was
performed using immunological assays and quantified using video-assisted microscopy at a single time-point.
Changes in nuclear shape, size, and numbers were used to provide additional support of initial findings. Each
experiment was conducted in triplicate. Specificity was assured by requiring that at least 2 different siRNAs
produced the observed change in each cell line/time-point/gene/assay combination.
Results: Knockdown of ARHGDIA, COBLL1, and TM4SF1 resulted in 2- to 4-fold increased levels of apoptosis in
normal cells (ARHGDIA only) and tumor cells (all three genes). No statistically significant changes were observed
in apoptosis after knockdown of PKM2 or for mitosis after knockdown of any gene.
Conclusions: We provide evidence that ARHGDIA, COBLL1, and TM4SF1 are negative regulators of apoptosis in
cultured tumor cells. These genes, and their related intracellular signaling pathways, may represent potential
therapeutic targets in mesothelioma.
Keywords: mesothelioma Cell biology/culture, Genes/polymorphisms, Genetics/genomics
Background
Malignant pleural mesothelioma (MPM) is a highly
lethal pleural cancer for which there are few effective
treatments and overall >90% five-year mortality.
Approximately 3,000 patients are diagnosed with MPM
i nt h eU Sa n n u a l l ya n dt h ei n c i d e n c ew o r l d w i d ei sp r o -
jected to rise substantially[1-3] owing to a lack of regu-
latory oversight governing the use of asbestos, the most
common cause for MPM (70-80%) [4-8].
MPM is characterized by multi-focal tumor growth
originating in the parietal pleura and often accompanied
by a pleural effusion. The tumor eventually spreads to
involve the visceral pleura producing a rind that con-
stricts the lung, heart and mediastinum. Presumably due
to the tumor’s location and rapid growth, death usually
results from compression of vital mediastinal structures
rather than from metastatic spread[7,9,10]. Without any
treatment, the expected median survival of patients
presenting with MPM is between 4 and 12 months.
Unfortunately, survival has not improved during the
past decade as MPM is exceedingly resistant to most
chemotherapy regimens. Pemetrexed and cisplatin com-
bination chemotherapy was shown in one of the few
positive prospective randomized trials to be the best
chemotherapy regimen for MPM. However, this therapy
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Radiation therapy is general l yi n e f f e c t i v ea sap r i m a r y
treatment as well [10,12].
Surgery-based multi-modal therapy has been
reported to improve survival in a subset of patients
who present with early MPM which is confined to a
single thoracic cavity. This treatment strategy includes
a complete surgical resection of the tumor utilizing an
extrapleural pneumonectomy followed by chemother-
apy with paclitaxel (or pemetrexed) and cisplatin fol-
lowed by whole chest external beam radiation therapy
to eradicate any residual disease. Up to 40% of selected
patients will survive for 5 years following treatment.
The majority, but not all, of these long-term survivors
have early stage disease as manifested by negative
lymph node status, low tumor volume and have epithe-
lial histology [10,13-19].
We have previously described[20] a molecular prog-
nostic test that is based on select ratios of mRNA
expression levels of 4 genes (TM4SF1, PKM2, COBLL1,
ARHGDIA) to predict outcome after surgery for
patients with MPM. Two of these genes (TM4SF1,
COBLL1) are expressed at higher levels in tumors asso-
ciated with a relatively good prognosis while the other
two (ARHGDIA, PKM2) are expressed at relatively
higher levels in tumors associated with a relatively poor
prognosis. This test was subsequently found to differ-
entiate between patients on the basis of postsurgical
outcome in multiple independent retrospective cohorts
[20,21]. Most recently, this test has been shown to inde-
pendently predict overall survival and cancer-specific
survival in a prospective clinical trial of patients under-
going surgery (i.e., extra-pleural pneumonectomy) for
MPM[22]. These studies indicate that the genes com-
prising the test are effective molecular markers for two
different MPM patient subsets, and thus could conceiva-
bly be used to rationally design clinical trials to test the
efficacy of proposed treatments targeting these specific
genes and related pathways. In this study, we have
begun to explore this possibility by determining whether
any of these 4 genes could be linked a cancer relevant
phenotype (e.g., mitosis, apoptosis) using a high-
throughput, cell-based RNA inhibition (RNAi) approach.
Methods
Cell lines and cell culture
The normal cell line WI38 and the tumor cell line A549
were purchased from the American Type Culture Col-
lection (http://www.atcc.org). Both cell lines were grown
in 384-well plates (4titude, Surrey, United Kingdom)
under RPMI1640 medium (Invitrogen, Carlsbad, Califor-
nia) supplemented with 10% calf serum and antibiotics.
A549 cells were grown in wells coated with collagen I
(BD Biosciences, San Jose, California).
Gene knockdown studies
A549 and WI38 cells were seeded at a density of
1,000 cells/well and 3,000 cells/well, respectively. One
day post-seeding, cells were separately transfected with
siRNAs (Applied Biosystems/Ambion Silencer
® siRNA
library, Austin, Texas) targeting positive control genes
(KIF11, PLK1) or experimental genes (ARHGDIA,
COBLL1, PKM2, TM4SF1) using Lipofectamine RNAi-
M a x( I n v i t r o g e n )a t0 . 0 9μl/well. A single siRNA mole-
cule was used for each positive control gene: KIF11
(siRNA ID #105925), PLK1 (siRNA ID #213548). Posi-
tive control genes were chosen to monitor the perfor-
m a n c eo ft h ea s s a ya se a c hg e n ei sw i d e l yk n o w nt o
affect both mitosis and apoptosis. Three structurally dis-
tinct siRNA molecules were separately used for each
experimental gene to confirm specificity of effect:
ARHGDIA (siRNA IDs #119694, #119695, #119907),
COBLL1 (siRNA IDs #136636, #136637, #136638),
PKM2 (siRNA IDs #285, #286, #287), TM4SF1 (siRNA
IDs #144307, #144308, #144309). All siRNAs were used
at a final concentration of 30 nM. Negative controls
consisted of scrambled, non-specific siRNAs and mock
transfection (i.e., transfection mix only). Positive and
negative controls were placed at multiple positions on
the plate to control for positional effects (if any). Each
cell line/siRNA molecule combination or cell line/mock
transfection combination was conducted in triplicate, i.
e., 3 wells per plate. All experiments were run in tripli-
cate with a single experiment consisting of one plate to
be used to assess knockdown efficiency (via quantitative
RT-PCR) and a separate identical plate to be used for
phenotypic and morphological assays described below.
Phenotypic studies of gene knockdown cell lines
Assessment of apoptosis and mitosis was conducted
using a high-throughput approach [23]based on compu-
ter-assisted automated analysis of captured microscopic
digital images [24,25], conducted as part of a fee-for-
service arrangement with Cenix Bioscience (http://www.
cenix-bioscience.com/). General strategies to minimize
false discoveries were used as previously described [26].
Essentially, siRNA-transfected and control adherent cells
were fixed at 72-hours post-transfection using 4% paraf-
ormaldehyde in PBS, washed using PBS, and stored at
4°C until analyzed further. Detection of apoptotic and
mitotic molecular markers was conducted using immuno-
logical assays after blocking in a buffer containing 0.1% Tri-
ton, 0.01% Saponin, and 4% BSA in PBS. Primary antibody
solutions (1:200 rabbit anti-cleaved lamin A in blocking
buffer for apoptosis; 1:900 mouse anti-phospho-histone
H3 in blocking buffer; 1:100 rabbit anti-alpha-tubulin in
blocking buffer to show cellular morphology) were applied
overnight at 4°C. All primary antibodies were obtained
from Cell Signaling Technology (Danvers, Massachusetts).
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for was applied for 2 h at RT (goat anti-rabbit alexa488,
goat anti-mouse alexa555, both antibodies from Invitrogen
in a dilution of 1:1,000 + 1 μg/ml Hoechst 33342, in block-
ing buffer). Cells were washed three times in PBS and
images were captured using an ImageXPress Micro auto-
mated microscope, with 10x objective, binning 2, 4 sites
per well, Dapi/FITC/Cy3/Cy5 channels. QC analysis of
digitally captured visual images containing fluorescent sig-
nals corresponding to apoptotic and mitotic molecular
markers, as well as Hoechst staining of cellular DNA, was
conducted using MetaMorph software (MDS Analytical
Technologies, Downingtown, Pennsylvania). Quantitative
auto-image analysis was conducted using eCognition soft-
ware (Definiens, Parsippany, New Jersey) with rule sets
optimized using data from positive control experiments.
Data quantification and analysis
Raw image data generated above was imported into
Spotfire DXP software (Tibco, Palo Alto, California) to
remove from consideration areas with high background,
bad focus, and/or image haze. Images were quantified
by first calculating a individual well average from 4
sites/well then calculating a triplicate average from the
three well averages, per sample, per readout. Experimen-
tal data was then normalized (to 100%) using the aver-
age of negative control data per sample, per readout.
For statistical analysis, the following indices were calcu-
lated: Apoptotic Index ({[number of cleaved lamin A
positive cells]/[number of nuclei]}*100%), Mitotic Index
({[number of phospho-histone H3 positive cells]/[num-
ber of nuclei]}*100%), Condensed Chromatin Index
({[number of condensed chromatin positive cells]/[num-
ber of nuclei]}*100%), Aberrant Nuclei Index ({[number
of aberrant nuclei]/[number of nuclei]}*100%), and the
Cell Number Index (absolute number of nuclei). The
Apoptotic and Mitotic Indices required co-localization
of Hoechst stain and cleaved lamin A or phosphor-
histone H3, respectively. The Condensed Chromatin and
Aberrant Nuclei Indices were based on Hoechst stain
intensity and nuclear shape parameters, respectively,
that were defined based on analysis of positive control
gene knockdown studies. Statistical analysis was per-
formed using a two-sided Student’s (parametric) t-test
for pair-wise comparisons of average experimental and
negative control index values. Data was initially col-
lected and analyzed for only the Apoptotic and Mitotic
Index. Therefore, to take into account multiple hypoth-
esis testing, statistical significance at the P < 0.05 level
was estimated by applying a corrective factor to experi-
mental P values such that statistical significance was
called when P < 0.00069 (i.e., 0.05/72 where 72 = 2 (cell
lines) × 2 (index readouts) × 3 (siRNAs per gene) × 6
(genes). Uncorrected P values were used to evaluate
subsequent indices (i.e., Condensed Chromatin, Aberrant
Nuclei, Cell Number) since these data were analyzed only
in tumor cells for the genes/siRNAs with statistically sig-
nificant differences (i.e., P < 0.00069) previously identi-
fied in the Apoptotic Index.
Quantitative RT-PCR
Total RNA was extracted from 384-well plates using
lysis buffer and the Invisorb kit (both from Invitek, Ber-
lin, Germany). RT reactions were set up using Applied
Biosystems (Foster City, California) HighCapacity cDNA
reagents and random hexamer primers following the
manufacturer’s recommended protocol. PCR reactions
w e r er u no na nA p p l i e dB i o s y s t e m s7 9 0 0 H Td e v i c e
using a SYBR Green fluorometric-based detection sys-
tem (SensiMix 2X PCR master mix, Quantace, Freising,
Germany). The total reaction volume was 11 μla n d
contained 500 nM of target specific primers[22]. Gene
expression levels in experimental knockdown cell lines
were expressed as a percentage of parental control.
Results
Targeting of MPM prognostic genes using RNAi
All 6 genes (2 positive control and 4 experimental) were
successfully targeted using 3 different siRNAs per gene as
shown by reduced mRNA levels in normal and tumor
knockdown cells relative to untransfected (parental) cells
(Figure 1). Negative control cells transfected with non-spe-
cific (i.e., scrambled) siRNAs were not associated with
changes in mRNA levels for any gene (data not shown).
Gene expression levels for positive controls (KIF11, PLK1)
and MPM prognostic genes (ARHGDIA, COBLL1, PKM2,
TM4SF1) were reduced by ~50-80% in normal cells
(Figure 1A). For reasons that were not immediately clear,
a slightly more efficient knockdown was achieved in
tumor cells (Figure 1B), as reflected by modestly reduced
variability and lower overall mRNA levels.
Detection of apoptosis and mitosis
Knockdown of ARHGDIA, COBLL1, and TM4SF1
resulted in increased levels of apoptosis in normal cells
(ARHGDIA only) and tumor cells (ARHGDIA, COBLL1,
TM4SF1) relative to negative controls. No changes were
observed in apoptosis after knockdown of PKM2 or for
mitosis after knockdown of any gene experimental gene. A
representative image is shown in Figure 2 for ARHGDIA
knockdown in tumor cells. To quantify these differences,
we calculated Apoptotic and Mitotic Indices and found
that apoptosis was statistically significantly elevated ~2- to
4-fold for silencing ARHGIA compared to negative con-
trol (siRNA1 P = 0.00067, siRNA2 P = 0.00098, siRNA3
P =8 . 7×1 0
-10) in normal cells (Figure 3A). Silencing of
other experimental genes were in some cases associated
w i t ham o d e s t l ye l e v a t e dd e g r e eo fa p o p t o s i st h a t ,a s
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siRNA (Figure 3A). A similar statistically significant 2- to
4-fold increase in the degree of apoptosis was observed
after knockdown of ARHGDIA (siRNA1 P =1 . 5×1 0
-6,
siRNA2 P =1 . 2×1 0
-8,s i R N A 3P =5 . 5×1 0
-9), COBLL1
(siRNA1 P = 1.3 × 10
-5, siRNA2 P = 1.8 × 10
-5, siRNA3 P
= 0.00063), and TM4SF1 (siRNA1 P = 7.3 × 10
-5, siRNA2
P =5 . 3×1 0
-5, siRNA3 P =3 . 2×1 0
-5), but not PKM2, in
tumor cells (Figure 3B). Despite a clear mitotic arrest after
knockdown of positive control genes, as expected no sta-
tistically significant changes were observed in the Mitotic
Index for any experimental gene relative to negative con-
trols (data not shown).
Morphological assessment of knockdown cell lines
We examined nuclear morphology in experimental and
control knockdown cell lines to look for relatively early
indicators of apoptosis in order to complement studies
described above in which apoptosis was measured using a
relatively late indicator (e.g., cleaved lamin A). The num-
bers of cells with condensed nuclei, a hallmark of apopto-
sis, were increased in all positive control and knockdown
cell lines that were previously associated with increased
apoptosis as measured using cleaved lamin A, (e.g., ARHG-
DIA, COBLL1, TM4SF1) but not in the single knockdown
cell line (PKM2) that was not. No statistically significant
changes were observed in the numbers of aberrantly
shaped nuclei under any circumstances by comparison of
values calculated for the Aberrant Nuclei Index between
experimental and controls (data not shown). A representa-
tive image is shown in Figure 4 for ARHGDIA knockdown
in tumor cells. To quantify these differences, we calculated
Condensed Chromatin and Aberrant Nuclei Indices. We
found that ARHGDIA, COBLL1, and TM4SF1 knockdown
Figure 1 RNAi-mediated knockdown of gene expression levels
in cultured cells. Levels of mRNA in normal (A) and tumor (B) cells
after transfection with 3 different siRNA molecules per gene as
represented by individual bars and expressed relative to
untransfected (parental) control cells. Error bars, SEM.
Figure 2 Phenotypic analysis of ARHGDIA knockdown cell lines. Tumor cells were transiently transfected with siRNAs targeting either
ARHGDIA (top panels) or non-specific siRNAs (bottom panel, “Neg”). Cells were fixed and fluorescently labeled 72 hours later using primary
antibodies to alpha-tubulin ("Tubulin”) to show cellular morphology only, phospho-histone H3 ("pHH3”) to mitosis, or cleaved lamin A to detect
apoptosis. Nuclei were visualized using Hoechst stain. No obvious differences were observed in the numbers of pHH3-labeled cells in
knockdown cells relative to negative control (based on total cell number) while the number of cleaved lamin A-positive cells were clearly
increased in knockdown cells relative to negative control.
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densed Chromatin Index (Figure 5A), although the results
were statistically significant (P < 0.05) for siRNAs asso-
ciated with a single experimental gene only (ARHGDIA;
siRNA1 P = 0.004, siRNA2 P = 0.001, siRNA3 P = 0.001).
As expected, no experimental gene/siRNA combination
from the Aberrant Nuclei Index was statistically signifi-
cantly (P < 0.05) different from the negative control.
Quantification of cell numbers in knockdown cell lines
T og e n e r a t eaC e l lN u m b e rI n d e x ,w eu s e da b s o l u t ec e l l
numbers (via enumeration of Hoechst-stained nuclei) as a
surrogate to determine the effects, if any, of experimental
gene knockdown on cellular proliferation. We found that
cell numbers decreased (relative to negative controls) in
ARHGDIA, COBLL1, and TM4SF1 knockdown cells
(Figure 5B) in support of previous results showing an
increase in apoptosis under the same conditions. The
observed decrease in cell number was statistically signifi-
cant (P < 0.05) for all siRNAs for each experimental gene
(gene, individual siRNA P v a l u e ) :A R H G D I A ,s i R N A 1
P = 0.012, siRNA2 P =2 . 0×1 0
-12,s i R N A 3P =0 . 0 3 9 ;
COBLL1, siRNA1 P = 0.008, siRNA2 P = 0.0006, siRNA3
P = 0.008; TM4SF1, siRNA1 P =2 . 0×1 0
-19,s i R N A 2P =
2.0 × 10
-5,s i R N A 3P =2 . 0×1 0
-11.
Discussion
Using an RNAi approach, we conducted in vitro gene
knockdown studies of the 4 genes comprising an MPM
prognostic test[20-22] and determined the effect, if any,
on cell death and growth arrest using molecular markers
for apoptosis and mitosis, respectively. Supporting data
was obtained in select positive experiments using cellu-
lar morphology. We have found that three of the MPM
prognostic genes (ARHGDIA, COBLL1, TM4SF1) are
associated with a phenotype consistent with a negative
regulator of apoptosis; rates of programmed cell death
increased ~2- to 4-fold when mRNA expression levels
for these genes were attenuated in cultured cells.
Increased apoptosis was also associated with concurrent
changes in nuclear morphology and a modest, but statis-
tically significant, reduction in cell number. The fourth
MPM prognostic gene (PKM2) could not be linked to
either apoptosis or growth arrest in the current study.
We established the Hoechst-based Condensed Chro-
matin Index as an apoptotic indicator secondary to the
detection of cleaved lamin A, a well established molecu-
lar marker[27]. We found that rates of apoptosis mea-
sured using this index were of a generally lower
magnitude compared to those obtained via detection of
cleaved lamin A, and furthermore not all genes linked
to apoptosis via cleaved lamin A were associated with a
statistically significant change in the Condensed Chro-
matin Index (e.g., COBLL1, TM4SF1), despite a trend in
the expected direction. This is likely due to the facts
that i) the index is based on clearly detectable nuclear
changes that are a hallmark of relatively early events in
apoptosis, such as local chromatin condensation while
cleaved lamin-A is a relatively late event, and ii) we col-
lected readouts at a single timepoint only (72 hours
post-siRNA transfection) by which point early apoptotic
events may have already occurred.
A second morphological readout (Aberrant Nuclei
Index) was collected to determine whether experimental
knockdown cells were associated with abnormally shaped
nuclei. The Aberrant Nuclei Index detects cells whose
nuclei deviate from the norm using two parameters,
Figure 3 Quantification of apoptosis after knockdown of MPM
prognostic genes in cultured cells. The Apoptotic Index was
calculated as described in the Methods in normal (A) and tumor
(B) cells transfected with 3 different siRNA molecules per gene
(as represented by individual bars) targeting MPM prognostic genes
("ARHGDIA”, “COBLL1”, “TM4SF1”, “PKM2”), positive control genes
("KIF11”, “PLK1”), or non-specific siRNAs as negative controls ("Neg”).
Error bars, SEM. *, statistically significant (P < 0.00069) relative to
negative control.
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and how oval nuclei are respectively. Changes in nuclear
morphology can be elicited by a number of different fac-
tors including, but not limited to fundamental alterations
to microfilament arrangement and the nuclear skeleton.
In addition to providing basic nuclear shape and stability,
nuclear support proteins are also required for chromatin
organization, transcription regulation, DNA replication,
nuclear assembly, nuclear positioning, and apoptosis.
Thus, the aberrant nuclei classification parameter may be
best described as a general marker for cell well-being. We
hypothesized that knockdown of MPM prognostic genes
that led to an increase in apoptosis would also lead to an
increase in the numbers of aberrantly shaped nuclei.
Although the frequency of aberrantly shaped nuclei was
modestly elevated under these expected conditions, the
results were not statistically significant. The implication of
this negative result, if any, is not clear and may relate to
timing issues and/or other factors since only 1 of the 2
apoptosis positive control knockdown cell lines displayed
a statistically significant increase in the numbers of aber-
rantly shaped nuclei.
The MPM prognostic genes examined in the current
study have in some cases been previously linked to can-
cer or cancer relevant processes. TM4SF1, a.k.a. L-6
tumor antigen, is a distant member of the transmem-
brane 4 superfamily of cell-surface proteins that are
characterized by the presence of four hydrophobic
domains. Although the precise function and physiologi-
cal role of this gene is unknown, the fact that it is a cell
surface antigen that is highly expressed in different
carcinomas and expressed at relatively low levels (if at
all) in many normal tissues has led to its evaluation as a
candidate therapeutic target for radioimmunotherapy
treatment, particularly for breast cancer[28]. More
recently, TM4SF1 has been linked to metastasis[29] and
angiogenesis[30], but not apoptosis (to our knowledge)
prior to the current study.
The COBLL1 (COBL-like 1) gene was cloned in 1999
and originally designated KIAA0977[31]. The deduced
protein contains 1,166 amino acids and was found to be
expressed at high levels in lung, liver, kidney, pancreas,
ovary, spinal cord, brain, fetal liver, and all specific adult
brain regions[31]. In 2003, Carroll et al. renamed the
gene COBBL1 based on homology to the newly discov-
ered COBL (i.e., cordon-bleu homolog, mouse) gene[32].
T h es p e c i f i cr o l e ( s )o fb o t hg e n e sa r en o tk n o w n ,b u t
each is presumed to play a role in embryogenesis based
on temporal expression patterns during development[32].
Given the known role of apoptosis in determining tissue
morphology during normal embryonic development and
the results of the current study, it is reasonable to
hypothesize that inappropriate expression in tumor cells
acts to prevent programmed cell death and promotes
tumor cell survival.
The ARHGDIA (Rho GDP dissociation inhibitor
[GDI] alpha) gene, first described in 1993[33], belongs a
family of genes whose members regulate (Ras superfam-
ily) Rho genes by keeping them in the inactive GDP-
bound state[34]. ARHGDIA was the only gene in our
RNAi studies found to impact apoptosis in both normal
and tumor cells, with a generally greater magnitude of
Figure 4 Morphological appearance of ARHGDIA knockdown cell lines. Tumor cells were transiently transfected with siRNAs targeting either
ARHGDIA (top panels) or non-specific siRNAs (bottom panel, “Neg”). Cells were fixed and fluorescently labeled 72 hours later using primary
antibodies to alpha-tubulin ("Tubulin”) to show cellular morphology only. Nuclei were visualized using Hoechst stain and classified as either
having condensed chromatin indicative of early apoptosis (green color, rightmost panels) and/or aberrantly shaped as a general indicator of cell
well-being (blue color, rightmost panels). No obvious differences were seen in the relative numbers of aberrantly shaped nuclei relative to
negative control while the numbers of cells containing condensed chromatin were increased in knockdown cells relative to negative control.
Gordon et al. BMC Cancer 2011, 11:169
http://www.biomedcentral.com/1471-2407/11/169
Page 6 of 9effect in tumor cells compared to the other 2 positive
genes. Other investigations of ARHGDIA in the context
of cancer have indicated a role in estrogen receptor sig-
nalling (and estrogen responsiveness) in breast cancer
[35,36] and association with poor prognosis in colorectal
cancer[37] consistent with our previous, similar findings
in MPM[20-22,37]. The normal physiological role of
ARHGDIA is likely to be tissue-specific since ARHG-
DIA (-/-) knockout mice are viable, but suffer severe
and progressive kidney and reproductive system impair-
ment and typically die within a year of birth[38]. While
the precise manner in which ARHGDIA regulates
apoptosis/cell survival in human cancer is not known,
studies in cultured rodent insulinoma cells show that
overexpression of ARHGDIA increased cell viability and
decreased activated c-Jun N-terminal kinase (JNK)
expression following exposure to the apoptosis promoter
mycophenolic acid (MPA), whereas knockdown of
ARHGDIA (via RNAi) enhanced MPA-induced cell
death and increased the activation of JNK[39].
Many types of cancer cells express the M2 isoform of
t h eg l y c o l y t i ce n z y m ep y r u v a t ek i n a s e( P K M 2 ) ,t h eo n l y
gene for which we could not provide evidence linking to
either an apoptosis and/or growth arrest phenotype. The
PKM2 gene product has been previously linked to cell
proliferation in vivo [3], presumably by increasing cellu-
lar metabolism, and is being evaluated for selective ther-
apeutic targeting based on preferential expression in
tumor, and not normal, cells[40]. PKM2 knockdown cell
lines in our hands did not display levels of apoptosis or
mitosis that differed meaningfully from controls which
may not be entirely unexpected given the known role of
this enzyme in metabolism and its hypothesized impor-
tance in tumor spreading[41], a phenotype we did not
measure in the current study. However, as would be
expected in a scenario of reduced metabolic activity and
decreased proliferation, knockdown of PKM2 was asso-
ciated with a modest (~15-20%) decrease in cell number
(via the Cell Number Index, as a surrogate measure of
proliferation) in two of three experiments employing dif-
ferent siRNA molecules, although the results were not
statistically significant due primarily to excessive
variability.
Although experimentally valid, a clear limitation of
our study is in the choice of cell lines modeled, neither
of which are mesothelioma-derived, although we have
no reason to believe that the basic mechanism of action
of any of these genes will differ dramatically among dif-
ferent tumor cell lines, although the strength of effect
may. WI38 cells are normal, human, lung-derived fibro-
blasts. A549 cells are derived from an alveolar (lung)
tumor. Several issues governed the choice of these cell
lines. MPM tumor cells are not easily amenable to high-
throughput assay conditions which we used to rapidly
screen a set of four genes to determine which, if any,
deserved further analysis in a traditional ("low through-
put”) one gene/one assay/one cell line experimental
design. A549 cells, unlike mesothelioma tumor cell
lines, are relatively easy to transfect and are more appro-
priate for use in a high-throughput assay. Also, there are
no established (normal) pleural mesothelial cell lines
available to use as a control. The general lack of knowl-
edge surrounding the precise function of the four
mesothelioma prognostic genes (ARHGDIA, COBLL1,
PKM2, TM4SF1) indicated the importance of examining
a normal cell line and WI38, while not ideal, was chosen
Figure 5 Quantification of cultured cells displaying aberrant
morphology after knockdown of MPM prognostic genes. The
Condensed Chromatin Index (A) and Cell Number Index (B) were
calculated as described in the Methods in tumor cell transfected
with 3 different siRNA molecules per gene (as represented by
individual bars) targeting MPM prognostic genes ("ARHGDIA”,
“COBLL1”, “TM4SF1”), positive control genes ("KIF11”, “PLK1”), or non-
specific siRNAs as negative controls ("Neg”). Error bars, SEM. *,
statistically significant (P < 0.05) relative to negative control.
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Page 7 of 9because it is of similar embryonic origin (i.e., mesoderm)
to mesothelial cells lining the thoracic pleura. Finally,
despite these limitations, we assert these studies as
described are still useful in that they add to the body of
knowledge for a set of relatively understudied genes.
Surgical resection for MPM has been reported to
improve survival in a subset of patients identified who
can be identified pre-operatively using proposed patho-
logical and molecule criteria[20-22]. Our results are
consistent with previous data that anti-apoptotic genes
are activated in MPM resulting in chemotherapy resis-
tance and tumor cell survival[42,43]. For example, the
fact that two of the genes (TM4SF1, COBLL1) are mole-
cular markers for relatively good prognosis patients
while the other one gene (ARHGDIA) is a molecular
marker for relatively poor prognosis patients suggest
that therapies could be tailored and tested in a rational
manner to target specific pathways activated in different
mesothelioma subsets.
Conclusion
We have examined the biological function of four vali-
dated prognostic genes for MPM and obtained evidence
that three of them are involved in some way with pro-
tecting the tumor cell from apoptosis. With further vali-
dation, these genes may thus provide new potential
targets for biological therapy of this deadly disease.
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